Yinhua CSI Chinese Medicine ETF(562390.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Yinhua CSI Chinese Medicine ETF
562390.SH
News
View More

The Health Department promotes a graded diversion mechanism for the approval of traditional Chinese medicine registration applications

The Department of Health announced that starting from January 1, 2026, it will pilot the "Tiered and Streamlined Review and Approval Arrangement for the Registration Applications of Traditional Chinese Medicine," adding two levels: "Innovative Drugs" and "Designated Priority Products," to expedite the processing of registration applications. The approval time for innovative drugs is 120 working days, while designated priority products will take 150 working days. The new mechanism aims to accelerate the approval speed, help enterprises plan their business and resources more effectively, and promote Hong Kong as an international hub for medical innovation

AASTOCKS·
SH
562390
-0.10%
SH
561510
-0.10%
AASTOCKS·
SH
562390
-0.10%
SH
561510
-0.10%

Lin Yuan: The aging population will benefit traditional Chinese medicine brands

Recently, Lin Yuan, Chairman of Shenzhen Linyuan Investment Management Co., Ltd. and a renowned investor, stated in an interview with reporters that, given the ongoing population aging, he remains optimistic about the traditional Chinese medicine industry in the future, especially the long-term development of time-honored traditional Chinese medicine brands, and emphasized that he will continue to focus on high-quality and scarce targets

Zhitong·
SH
562390
-0.10%
Zhitong·
SH
562390
-0.10%

The Department of Consumer Goods Industry of the Ministry of Industry and Information Technology conducted research on the Chinese medicine industry in Beijing

The Department of Consumer Goods Industry of the Ministry of Industry and Information Technology and the Beijing Municipal Bureau of Economy and Information Technology conducted a research on the entire industrial chain of Chinese medicine in Beijing, emphasizing the need to start from the source and promote the large-scale, standardized, and ecological development of Chinese medicinal materials cultivation. The research team encouraged collaborative efforts around key common technologies to enhance the modernization, digital intelligence, and greening of Chinese medicine manufacturing, support the industrialization of new drug research and development in Chinese medicine and the formulation development results of medical institutions, in order to meet clinical needs

Zhitong·
SH
562390
-0.10%
Zhitong·
SH
562390
-0.10%

The 2025 Jiangxi Pharmaceutical Development Conference held with 16 key pharmaceutical projects signed in concentration

The 2025 Jiangxi Pharmaceutical Development Conference was held on the 25th in Ganzhou City, where 16 key pharmaceutical projects were signed. The key pharmaceutical projects signed cover multiple fields, including innovative drugs, traditional Chinese medicine, pet medicine, medical devices, and pharmaceutical technology innovation platforms

Zhitong·
SH
562390
-0.10%
Zhitong·
SH
562390
-0.10%

Research shows: Traditional Chinese medicine provides new options to combat certain types of "superbugs."

Research shows that the traditional Chinese medicine compound Xinjia Dayuan Powder demonstrates significant advantages in treating multidrug-resistant Gram-negative bacterial pneumonia, providing a new option for combating "superbugs." After two years of clinical trials, the research results have been published in the international journal "Phytomedicine." Experts point out that this discovery offers patients an auxiliary treatment option and further proves the unique value of traditional Chinese medicine in treating difficult diseases

Zhitong·
SH
562390
-0.10%
SH
561510
-0.10%
Zhitong·
SH
562390
-0.10%
SH
561510
-0.10%
© 2026 Longbridge｜Disclaimer